PDS Biotechnology (Nasdaq:PDSB) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

PDSB Stoklara Genel Bakış

PDSB temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 76.57% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Son 3 ayda dalgalı hisse senedi fiyatı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

PDS Biotechnology Corporation Rakipler

Vigil Neuroscience

NasdaqGS:VIGL

US$136.4m

Kodiak Sciences

NasdaqGM:KOD

US$139.1m

Tenaya Therapeutics

NasdaqGS:TNYA

US$136.5m

aTyr Pharma

NasdaqCM:ATYR

US$147.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti PDS Biotechnology
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.40
52 Haftanın En Yüksek Seviyesi	US$6.85
52 Haftanın En Düşük Seviyesi	US$2.53
Beta	1.9
11 Aylık Değişim	12.96%
3 Aylık Değişim	-12.37%
1 Yıllık Değişim	-26.88%
33 Yıllık Değişim	-75.24%
5 Yıllık Değişim	-2.02%
Halka arzdan bu yana değişim	-60.05%

Son Haberler & Güncellemeler

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

Feb 03

PDS Biotechnology gives new CFO ~202K stock grant

Jan 06

Hissedar Getirileri

	PDSB	US Biotechs	US Pazar
7D	-17.3%	-1.0%	1.2%
1Y	-26.9%	17.9%	31.0%

Getiri vs. Endüstri: PDSB geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: PDSB geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is PDSB's price volatile compared to industry and market?
PDSB volatility
PDSB Average Weekly Movement	10.6%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: PDSB hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: PDSB 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2005	25	Frank Bedu-Addo	www.pdsbiotech.com

Klinik aşamada bir biyofarmasötik şirketi olan PDS Biotechnology Corporation, Amerika Birleşik Devletleri'nde hedefe yönelik kanser immünoterapilerinden oluşan bir boru hattı geliştirmektedir. Şirketin öncü ürün adayı, tekrarlayan/metastatik baş ve boyun kanseri ve insan papilloma virüsü ile ilişkili maligniteler için birinci basamak tedavi sağlayan Faz II klinik çalışmasında olan PDS0101'dir (HPV16). Ayrıca, prostat ve meme kanserlerini tedavi etmek için tümörle ilişkili ve immünolojik olarak aktif T hücre reseptörü gama alternatif okuma çerçeveli protein (TARP) kullanan bir araştırma immünoterapisi olan PDS0102 ve yumurtalık, kolorektal, akciğer ve meme kanserleri için PDS0103 dahil olmak üzere klinik öncesi çalışmalarda olan çeşitli ürün adayları geliştirmektedir.

PDS Biotechnology Corporation Temel Bilgiler Özeti

PDS Biotechnology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PDSB temel i̇stati̇sti̇kler
Piyasa değeri	US$131.08m
Kazançlar(TTM)	-US$40.68m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-3.1x

F/K Oranı

PDSB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PDSB gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$40.68m
Kazançlar	-US$40.68m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.10
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	78.4%

PDSB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PDSB Stoklara Genel Bakış

Ödüller

Risk Analizi

PDS Biotechnology Corporation Rakipler

NasdaqGS:VIGL

US$136.4m

NasdaqGM:KOD

US$139.1m

NasdaqGS:TNYA

US$136.5m

NasdaqCM:ATYR

US$147.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

New major risk - Revenue and earnings growth

PDS Biotechnology Corporation to Report Q2, 2024 Results on Aug 13, 2024

Pds Biotech Aligns with Fda on Phase 3 Trial in Hpv16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotechnology Corporation(NasdaqCM:PDSB) dropped from Russell Small Cap Completeness Index

Recent updates

PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

New major risk - Revenue and earnings growth

PDS Biotechnology Corporation to Report Q2, 2024 Results on Aug 13, 2024

Pds Biotech Aligns with Fda on Phase 3 Trial in Hpv16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotechnology Corporation(NasdaqCM:PDSB) dropped from Russell Small Cap Completeness Index

New minor risk - Market cap size

PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2024 Results on May 15, 2024

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

PDS Biotechnology Corporation Announces Publication of Preclinical Research

PDS Biotechnology Corporation Announces Executive Changes

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Pds Biotech Announces CFO Changes

Price target decreased by 8.4% to US$17.67

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023

PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO

PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

New major risk - Financial position

PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial

PDS Biotechnology Corporation to Report Q2, 2023 Results on Aug 14, 2023

PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023

PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of Versamune®? and PDS0301

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients

Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Price target increased by 7.9% to US$19.43

PDS Biotechnology Corporation Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune

PDS Biotechnology Corporation Announces Preclinical Studies Involving Infectimune

PDS Biotechnology Corporation Announces Abstract Accepted for Presentation At ESMO Targeted Anticancer Therapies Congress

PDS Biotechnology Corporation Reports Median Overall Survival of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 Months

Price target increased to US$18.25

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

President exercised options and sold US$562k worth of stock

Price target increased to US$18.00

PDS Biotechnology Corporation Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from Immunocerv Phase 2 Clinical Trial

PDS Biotechnology Corporation Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

PDS Biotechnology Corporation to Report Q3, 2022 Results on Nov 14, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

PDS Biotechnology Corporation Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

Price target decreased to US$17.71

PDS Biotechnology Corporation Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA(R)

PDS Biotech jumps 13% as FDA clears further development of lead asset

PDS Biotechnology Corporation Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

PDS Biotechnology files for $150 mixed shelf offering

PDS Biotech Independent Data Monitoring Committee Recommends Versatile-002 Trial Continuation Without Modifications

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

PDS Biotechnology Corporation to Report Q2, 2022 Results on Aug 08, 2022

PDS Biotechnology Corporation Announces Presentation of Universal Flu Vaccine Preclinical Data At American Society of Virology Meeting